IL wins patent infringement lawsuit against Diagnostica Stago
Diagnostica Stago to cease manufacturing and selling STA-Staclot APC-R kits and Stagen Kit FVM Mutation
Instrumentation Laboratory and its parent company Instrumentation Laboratory SpA or IL have reported that the Paris First Level Civil Court has determined that Diagnostica Stago infringed the French counterparts of two European patents licensed exclusively to IL, and committed acts of unfair competition due to denigrating advertisements.
As a result, the court ruled in part that: Diagnostica Stago must cease manufacturing and selling its infringing products, STA-Staclot APC-R kits and Stagen Kit FVM Mutation, and must cease denigrating advertisements concerning IL's products; Diagnostica Stago's inventory of STA-Staclot APC-R kits and Stagen Kit FVM Mutation may be confiscated for potential future destruction; and Diagnostica Stago must pay IL the sum of approximately $2.6 million as an advance on damages for the infringement and unfair competition, plus attorneys' fees. The court's decision may be appealed.
IL is the exclusive licensee of two patents covering inventions from Bjorn Dahlback, relating to the detection of thrombophilia, a coagulation disorder, in human blood. The first patent relates to a method for diagnosing a human blood coagulation disorder called resistance to APC (also known as activated protein C resistance), while the second patent additionally relates to a method for determining the presence of gene mutations of Factor V, which is one of the causes of thrombophilia.
Josep Manent, CEO at IL, said: Litigation is not our first preference. However, our belief that Diagnostica Stago violated our patent rights and unfairly advertised by disparaging IL's product, forced us to pursue legal action. We are pleased with the court's decision.
Related Insight
Suppliers Directory
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Regulatory Affairs Intelligence
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.